Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without Myeloablation

Dunbar, Cynthia E., Kohn, Donald B., Schiffmann, Raphael, Barton, Norman W., Nolta, Jan A., Esplin, Joan A., Pensiero, Michael, Long, Zhifeng, Lockey, Chris, Emmons, Robert V.B., Csik, Susie, Leitman, Susan, Krebs, Connie B., Carter, Charles, Brady, Roscoe O., Karlsson, Stefan · 1998 · Human Gene Therapy

Abstract

Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6–15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (<0.02%) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease. In this study a retroviral vector is used to transduce human hematopoietic cells in order to explore whether gene marking of these target cells can be obtained in vivo following gene transfer and infusion of the transduced cells into nonmyeloablated recipients. Hematopoietic cells containing the glucocerebrosidase cDNA from the vector were detected up to 3 months after infusion of the transduced cells into patients with Gaucher disease. The level of gene marking was low and the glucocerebrosidase enzyme activity was not increased following transduction and infusion. The results show that it is possible to achieve gene marking in vivo following transplantation of gene-transduced hematopoietic cells into nonmyeloablated recipients. However, the efficiency of the procedure needs to be improved greatly to obtain therapeutic effects for genetic disorders of the hematopoietic system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/10430349850019463

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Dunbar, C. E., Kohn, D. B., Schiffmann, R., Barton, N. W., Nolta, J. A., Esplin, J. A., Pensiero, M., Long, Z., Lockey, C., Emmons, R. V. B., Csik, S., Leitman, S., Krebs, C. B., Carter, C., Brady, R. O., & Karlsson, S.
Venue
Human Gene Therapy
Published
1998-11-20
Volume
9
Issue
17
Pages
2629-2640
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2027321452
Cited by
174
References
1
FWCI
7.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without Myeloablation. https://app.cochat.ai/papers/10.1089/10430349850019463
The paper
Dunbar, C. E., Kohn, D. B., Schiffmann, R., Barton, N. W., Nolta, J. A., Esplin, J. A., Pensiero, M., Long, Z., Lockey, C., Emmons, R. V. B., Csik, S., Leitman, S., Krebs, C. B., Carter, C., Brady, R. O., & Karlsson, S. (1998). Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without Myeloablation. Human Gene Therapy. https://doi.org/10.1089/10430349850019463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.